We demonstrated that AD-O51.4 sensitivity can be increased by blocking DR internalization (dynasore), blocking BCL2 antiapoptotic activity (venetoclax) or by modulating epigenetic mechanisms, such as histone acetylation (SAHA, panobinostat). This evidence concerns the gene BCL2 and Alzheimer disease.